MYO’s Growth Playbook: Myomo’s Q2 Jump and the Recurring-Revenue Pivot

Executive snapshot

Myomo, Inc. (ticker: MYO) reported its second-quarter 2026 financials with a revenue print of $11.7 million, a 21% year-over-year increase. The company frames this as the result of a deliberate push toward recurring patient sources and broader payer access, a strategy that could start to show up in margins as operating expenses stay roughly flat alongside growing top-line activity.

The release also notes a shift in the revenue mix: 53% of Q2 revenue came from recurring patient sources—provider referrals, O&P partners, and the VA—up from a year ago. In other words, the company is turning patients into a more dependable revenue stream, not just chasing one-off orders.

Key numbers and metrics

Revenue: $11.7 million for the quarter, +21% YoY
Recurring sources: 53% of Q2 revenue from referrals and partner channels
Market access: Expanded payer contracts; in-network access to >100 million lives
Guidance: Full-year revenue forecast raised to $45–$47 million
Operational leverage: Revenue growth accompanied by roughly flat operating expenses

Strategic pillars and takeaways

Shift to Recurring Patient Sources: The company notes that 53% of Q2 revenue came from recurring channels, elevating the visibility of revenue stability and potential earnings consistency over time. This isn’t a one-off win; it’s a structural shift toward more predictable cash inflows.

Increase Market Access with Additional Payer Contracts: The press release highlights added state contracts via Elevance’s Anthem Blue Cross Blue Shield Network, with in-network access to more than 100 million covered lives. This expands the potential addressable market and could support longer-term revenue visibility.

Management commentary

CEO Paul R. Gudonis framed the quarter as evidence that the company’s go-to-market approach is “driving positive results.” He noted revenue of $11.7 million came with 53% of sales from referral networks and other channels, and he signaled continued progress on these initiatives. The guidance change to a higher revenue forecast suggests the company believes the trajectory can extend beyond the current quarter.

Implications for earnings and peers

Even with no EPS figure disclosed in the release, the operating leverage story is the key insinuation: if revenue continues to grow while fixed costs stay flat, EPS could improve, potentially creating an earnings surprise relative to EPS consensus expectations from analysts. The company’s revenue forecast for 2026 now sits at $45–$47 million, implying mid-to-high single-digit to low-double-digit top-line growth depending on the quarter. How this translates to earnings remains fluid, contingent on mix, payer reimbursements, and the pace of cost containment.

From a sector perspective, Myomo’s emphasis on payer access and recurring channels mirrors a broader investor appetite for durable demand drivers in medical devices and assistive robotics. If these channels prove durable, peers addressing neuromuscular support devices and rehab tech could face similar questions from investors about revenue visibility and margin expansion, not merely top-line momentum.

What to watch next

Key near-term milestone: the conference call at 4:30 p.m. Eastern today, where management will likely expand on the trajectory of the MyoConnect program, O&P partnerships, and payer negotiations. Investors will parse whether the revenue ramp can sustain the raised revenue forecast and whether operating expenses remain disciplined, a necessary condition for turning top-line strength into a meaningful EPS uplift.

Look for any revisions to guidance, commentary on patient volume mix, and signs that the company’s “four pillars” fueling growth are accelerating rather than plateauing. In the world of small-cap healthcare tech, a reliable top line is the floor; margins are the ceiling—and the ceiling, here, is still a work in progress.

Closing thoughts

Myomo’s Q2 results present a narrative of revenue stability stitched to growth. The shift toward recurring sources and expanded payer coverage creates a more tangible path to profitability, even if the arithmetic of EPS remains to be proven in the numbers. For investors, the stock’s near-term appeal hinges on whether this revenue forecast can translate into durable earnings power, and whether the company can sustain the pace of payer-contract progress seen in the quarter. If the trend holds, sector peers might find themselves judged less by flashy quarterly deltas and more by the steadiness of their revenue forecast and the discipline of their cost structure.